Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2025, compared to $850.7 million as of December 31, 2024. Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2025, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2028. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics reports Q2 EPS ($1.00), consensus ($1.09)
- Beam Therapeutics provides updata on BEAM-302 development progress
- Analysts Spot 3 Strong Buy Russell 2000 Stocks with 100% Upside
- Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off
- Cathie Wood’s ARK Investment buys 659K shares of Beam Therapeutics today